Can-Fite BioPharma Ltd. (NYSE:CANF) Short Interest Update

Posted by Andrew Walz on Oct 6th, 2025

Can-Fite BioPharma Ltd. (NYSE:CANF – Get Free Report) saw a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 102,500 shares, a decline of 42.7% from the August 31st total of 179,000 shares. Based on an average daily volume of 198,500 shares, the short-interest ratio is presently 0.5 days. Based on an average daily volume of 198,500 shares, the short-interest ratio is presently 0.5 days.

Institutional Investors Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers boosted its position in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 42.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 38,268 shares of the company’s stock after acquiring an additional 11,388 shares during the period. Rhumbline Advisers owned 1.08% of Can-Fite BioPharma worth $57,000 at the end of the most recent reporting period. 21.00% of the stock is owned by institutional investors and hedge funds.

Can-Fite BioPharma Price Performance

NYSE CANF opened at $0.63 on Monday. Can-Fite BioPharma has a 1 year low of $0.59 and a 1 year high of $3.12. The stock has a market capitalization of $2.24 million, a PE ratio of -0.35 and a beta of 1.01. The company’s 50 day simple moving average is $0.66 and its two-hundred day simple moving average is $0.98.

Analysts Set New Price Targets

Separately, D. Boral Capital restated a “buy” rating and issued a $11.00 target price on shares of Can-Fite BioPharma in a report on Tuesday, September 16th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Can-Fite BioPharma currently has a consensus rating of “Buy” and a consensus price target of $14.50.

Read Our Latest Report on Can-Fite BioPharma

Can-Fite BioPharma Company Profile

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.